Data Validating the Utility of RosettaGX Reveal™ with Liquid-based Cytology Samples will be Presented at the 86th Annual Me...
September 14 2016 - 9:09AM
Business Wire
Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and
provider of microRNA-based and other molecular diagnostics, today
announces the results from an analytical validation study
confirming that the Company’s first-of-its-kind microRNA classifier
for indeterminate thyroid nodules, RosettaGX Reveal™ (“Reveal”),
can now be used with liquid-based cytology samples (ThinPrep®). The
data will be presented in a poster at the upcoming 86th Annual
Meeting of the American Thyroid Association taking place from
September 21-25, 2016 at the Sheraton Denver Downtown Hotel in
Denver, Colorado.
Data highlighting the utility of RosettaGX Reveal with ThinPrep
samples will be available for viewing as follows:
Poster Title:
“Analytical Validation of a microRNA-based
Diagnostic Assay for Using Liquid-Based Cytology Samples”
Poster Number: Short Call Poster 52 Date/Time: September 23, 2016
from 9:30 a.m. – 5:30 p.m. Location: Exhibit Hall Presenters:
Dganit Bar, PhD, Chief Scientific Officer, Rosetta Genomics Nicole
Massol, MD, Director of Cytopathology, University of Arkansas
Medical Sciences Eti Meiri, PhD, Vice President
Research—Diagnostics, Rosetta Genomics
ThinPrep® is a registered trademark of Hologic, Inc.
About Rosetta Genomics
Rosetta develops and commercializes a full range of
microRNA-based and other molecular diagnostics. Rosetta’s
integrative research platform combining bioinformatics and
state-of-the-art laboratory processes has led to the discovery of
hundreds of biologically validated novel human microRNAs. Building
on its strong patent position and proprietary platform
technologies, Rosetta is working on the application of these
technologies in the development and commercialization of a full
range of microRNA-based diagnostic tools. Through the acquisition
of PersonalizeDx, the Company now offers core FISH, IHC and
PCR-based testing capabilities and partnerships in Pathology,
Oncology and Urology that provide additional content and platforms
that complement Rosetta’s microRNA and Next-Gen Sequencing
offerings. RosettaGX Reveal™, a Thyroid microRNA Classifier for the
diagnosis of indeterminate thyroid FNA smears, as well as the full
RosettaGX™ portfolio of cancer testing services are commercially
available through the Company’s Philadelphia, PA- and Lake Forest,
CA-based CAP-accredited, CLIA-certified labs. For more information
visit www.rosettagx.com.
Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta’s future
expectations, plans and prospects constitute forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including
those risks more fully discussed in the "Risk Factors" section of
Rosetta’s most recently filed Annual Report on Form 20-F, as filed
with the SEC. In addition, any forward-looking statements represent
Rosetta’s views only as of the date of this release and should not
be relied upon as representing its views as of any subsequent date.
Rosetta does not assume any obligation to update any
forward-looking statements unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160914005727/en/
Rosetta Genomics:Ken Berlin, 267-298-1159President &
CEOinvestors@rosettagx.comorRosetta Genomics
Investors:LHAAnne Marie Fields,
212-838-3777afields@lhai.com
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rosetta Genomics (CE) (USOTC:ROSGQ)
Historical Stock Chart
From Apr 2023 to Apr 2024